Tessa Therapeutics (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments, today announced the appointment of David McIntyre as its Chief Financial Officer.
The results of the preclinical study, a collaboration between Tessa Therapeutics and Baylor College of Medicine, were presented at the 2019 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Washington, D.C.